# BlackRock TCP Capital Corp.: financial statements, quarterly

TCPC · Nasdaq · CIK 1370755 · [Other](/sectors/other.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/tcpc.md) · [Financials](/companies/tcpc/financials.md) · [Filings](/companies/tcpc/filings.md) · [Insiders](/companies/tcpc/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/tcpc/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Net income | $m | [12.8](/filings/0000950170-24-121829.md) | [(13.3) d](/filings/0001193125-26-079299.md) | [5.1](/filings/0000950170-25-066415.md) | [(51.3)](/filings/0000950170-25-104590.md) | [21.6](/filings/0001193125-25-268125.md) | [(38.6) d](/filings/0001193125-26-079299.md) | [20.9](/filings/0001193125-26-210632.md) | [(15.9)](/filings/0001193125-26-336794.md) | [24.4](/filings/0001193125-25-268125.md) | [(118) d](/filings/0001193125-26-079299.md) | [(16.3)](/filings/0001193125-26-210632.md) | [1.7](/filings/0001193125-26-336794.md) |
| Diluted EPS | $ per share | [0.25](/filings/0000950170-25-066415.md) | not reported | [0.08](/filings/0000950170-25-066415.md) | [(0.60)](/filings/0000950170-25-104590.md) | [0.25](/filings/0001193125-25-268125.md) | not reported | [0.25](/filings/0001193125-26-210632.md) | [(0.19)](/filings/0001193125-26-336794.md) | [0.29](/filings/0001193125-25-268125.md) | not reported | [(0.19)](/filings/0001193125-26-210632.md) | [0.02](/filings/0001193125-26-336794.md) |
| Basic EPS | $ per share | [0.25](/filings/0000950170-25-066415.md) | not reported | [0.08](/filings/0000950170-25-066415.md) | [(0.60)](/filings/0000950170-25-104590.md) | [0.25](/filings/0001193125-25-268125.md) | not reported | [0.25](/filings/0001193125-26-210632.md) | [(0.19)](/filings/0001193125-26-336794.md) | [0.29](/filings/0001193125-25-268125.md) | not reported | [(0.19)](/filings/0001193125-26-210632.md) | [0.02](/filings/0001193125-26-336794.md) |

- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-23) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [91.7](/filings/0000950170-23-057753.md) | [112](/filings/0000950170-24-092283.md) | [121](/filings/0000950170-24-050900.md) | [195](/filings/0000950170-24-092283.md) | not reported | [91.6](/filings/0001193125-26-079299.md) | not reported | [107](/filings/0000950170-25-104590.md) | [61.0](/filings/0001193125-25-268125.md) | [61.1](/filings/0001193125-26-336794.md) | [93.3](/filings/0001193125-26-210632.md) | [400](/filings/0001193125-26-336794.md) |
| Total assets | $m | [1,719](/filings/0000950170-23-057753.md) | [1,699](/filings/0000950170-25-028389.md) | [2,284](/filings/0000950170-24-050900.md) | [2,219](/filings/0000950170-24-092283.md) | [2,048](/filings/0000950170-24-121829.md) | [1,923](/filings/0001193125-26-079299.md) | [1,899](/filings/0000950170-25-066415.md) | [1,937](/filings/0000950170-25-104590.md) | [1,811](/filings/0001193125-25-268125.md) | [1,650](/filings/0001193125-26-336794.md) | [1,510](/filings/0001193125-26-210632.md) | [1,476](/filings/0001193125-26-336794.md) |
| Total liabilities | $m | [984](/filings/0000950170-23-057753.md) | [1,011](/filings/0000950170-25-028389.md) | [1,330](/filings/0000950170-24-050900.md) | [1,346](/filings/0000950170-24-092283.md) | [1,182](/filings/0000950170-24-121829.md) | [1,138](/filings/0001193125-26-079299.md) | [1,118](/filings/0000950170-25-066415.md) | [1,196](/filings/0000950170-25-104590.md) | [1,071](/filings/0001193125-25-268125.md) | [1,052](/filings/0001193125-26-336794.md) | [944](/filings/0001193125-26-210632.md) | [924](/filings/0001193125-26-336794.md) |
| Long-term debt | $m | [970](/filings/0000950170-23-057753.md) | [985](/filings/0000950170-25-028389.md) | [1,303](/filings/0000950170-24-050900.md) | [1,320](/filings/0000950170-24-092283.md) | [1,160](/filings/0000950170-24-121829.md) | [1,118](/filings/0001193125-26-079299.md) | [1,099](/filings/0000950170-25-066415.md) | [1,175](/filings/0000950170-25-104590.md) | [1,052](/filings/0001193125-25-268125.md) | [1,036](/filings/0001193125-26-336794.md) | [926](/filings/0001193125-26-210632.md) | [911](/filings/0001193125-26-336794.md) |
| Shareholders' equity | $m | [735](/filings/0000950170-24-121829.md) | [688](/filings/0001193125-26-079299.md) | [953](/filings/0001193125-25-268125.md) | [873](/filings/0001193125-25-268125.md) | [866](/filings/0001193125-25-268125.md) | [785](/filings/0001193125-26-336794.md) | [781](/filings/0001193125-26-336794.md) | [740](/filings/0001193125-26-336794.md) | [740](/filings/0001193125-25-268125.md) | [598](/filings/0001193125-26-336794.md) | [565](/filings/0001193125-26-336794.md) | [552](/filings/0001193125-26-336794.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue, us-gaap:Cash
- Total assets: us-gaap:Assets
- Total liabilities: us-gaap:Liabilities
- Long-term debt: us-gaap:LongTermDebt
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [46.6 d](/filings/0000950170-24-121829.md) | [40.3 d](/filings/0001193125-26-079299.md) | [33.4](/filings/0000950170-25-066415.md) | [86.4 d](/filings/0000950170-25-104590.md) | [102 d](/filings/0001193125-25-268125.md) | [71.7 d](/filings/0001193125-26-079299.md) | [52.5](/filings/0001193125-26-210632.md) | [(41.9) d](/filings/0001193125-26-336794.md) | [104 d](/filings/0001193125-25-268125.md) | [40.5 d](/filings/0001193125-26-079299.md) | [159](/filings/0001193125-26-210632.md) | [96.3 d](/filings/0001193125-26-336794.md) |
| Dividends paid | $m | [25.4 d](/filings/0000950170-24-121829.md) | [34.1 d](/filings/0001193125-26-079299.md) | [7.3](/filings/0001193125-26-079299.md) | [48.7 d](/filings/0000950170-25-104590.md) | [29.1 d](/filings/0001193125-25-268125.md) | [37.4 d](/filings/0001193125-26-079299.md) | [24.7](/filings/0001193125-26-210632.md) | [24.7 d](/filings/0001193125-26-336794.md) | [24.7 d](/filings/0001193125-25-268125.md) | [21.2 d](/filings/0001193125-26-079299.md) | [14.3](/filings/0001193125-26-210632.md) | [14.3 d](/filings/0001193125-26-336794.md) |
| Share repurchases | $m | not reported | not reported | [0.0](/filings/0000950170-25-066415.md) | [0.0 d](/filings/0000950170-25-104590.md) | [0.0 d](/filings/0001193125-25-268125.md) | [4.5 d](/filings/0001193125-26-079299.md) | [0.0](/filings/0001193125-26-210632.md) | [0.3 d](/filings/0001193125-26-336794.md) | [0.2 d](/filings/0001193125-25-268125.md) | [2.5 d](/filings/0001193125-26-079299.md) | [2.3](/filings/0001193125-26-210632.md) | [0.6 d](/filings/0001193125-26-336794.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Dividends paid: us-gaap:PaymentsOfDividends
- Share repurchases: us-gaap:PaymentsForRepurchaseOfCommonStock

## Shares

| Line item | Unit | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [57.8](/filings/0000950170-23-057753.md) | [57.8](/filings/0000950170-24-050900.md) | [57.8](/filings/0000950170-24-092283.md) | [57.8](/filings/0000950170-24-121829.md) | [62.0](/filings/0000950170-25-066415.md) | [85.6](/filings/0000950170-25-104590.md) | [85.6](/filings/0001193125-25-268125.md) | [85.1](/filings/0001193125-26-210632.md) | [85.0](/filings/0001193125-26-336794.md) | [85.0](/filings/0001193125-25-268125.md) | [84.3](/filings/0001193125-26-210632.md) | [83.9](/filings/0001193125-26-336794.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 83,902,775 at 2026-08-06, from the cover of the [10-Q filed 2026-08-06](/filings/0001193125-26-336794.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:38 ET. No prices; not investment advice.